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Complement component 1 Q subcomponent-binding protein (C1QBP; also known as p32) is a multi-compartmental protein whose pre- 
cise function remains unknown. It is an evolutionary conserved multifunctional protein localized primarily in the mitochondrial matrix 
and has roles in inflammation and infection processes, mitochondrial ribosome biogenesis, and regulation of apoptosis and nuclear 
transcription. It has an N-terminal mitochondrial targeting peptide that is proteolytically processed after import into the mitochondrial 
matrix, where it forms a homotrimeric complex organized in a doughnut-shaped structure. Although C1QBP has been reported to exert 
pleiotropic effects on many cellular processes, we report here four individuals from unrelated families where biallelic mutations in 
C1QBP cause a defect in mitochondrial energy metabolism. Infants presented with cardiomyopathy accompanied by multisystemic 
involvement (liver, kidney, and brain), and children and adults presented with myopathy and progressive external ophthalmoplegia. 
Multiple mitochondrial respiratory-chain defects, associated with the accumulation of multiple deletions of mitochondrial DNA in 
the later-onset myopathic cases, were identified in all affected individuals. Steady-state C1QBP levels were decreased in all individuals’ 
samples, leading to combined respiratory-chain enzyme deficiency of complexes I, III, and IV. C1qbp-/- mouse embryonic fibroblasts 
(MEFs) resembled the human disease phenotype by showing multiple defects in oxidative phosphorylation (OXPHOS). Complementa- 
tion with wild-type, but not mutagenized, C1qbp restored OXPHOS protein levels and mitochondrial enzyme activities in C1qbp-/- 
MEFs. C1QBP deficiency represents an important mitochondrial disorder associated with a clinical spectrum ranging from infantile 
lactic acidosis to childhood (cardio)myopathy and late-onset progressive external ophthalmoplegia. 
 
Introduction 
 
Mitochondrial disorders are an extremely heterogeneous 
group of inborn errors of metabolism and encompass a 
wide range of clinical presentations, such that approxi- 
mately 300 disease-associated  genes have been identified  
to date.1,2 Mitochondrial dysfunction mainly affects or-  
gans with high energy requirements, such as the brain, 
central nervous system, muscle, and heart. The broad clin- 
ical and genetic presentation of mitochondrial disorders 
makes the molecular diagnosis challenging. Mutations 
can directly affect oxidative phosphorylation (OXPHOS) 
subunits or indirectly impair OXPHOS activity by 
disturbing mitochondrial homeostasis. Next-generation 
sequencing techniques (gene panels and exome and 
genome sequencing) are proving to be an appropriate 
tool for the diagnosis of this broad clinical group. However, 
any diagnostic approach continues to rely upon deep 
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 clinical phenotyping in association with the evaluation of 
OXPHOS enzymes in tissues of affected individuals.3–6 
Combined defects of complexes I, III, IV, and V are typi- 
cally due to deficiencies involving the homeostasis of 
mitochondrial DNA (mtDNA), including defects in replica- 
tion, RNA metabolism, and translation.1,7 Moreover, 
mtDNA rearrangements can lead to combined OXPHOS 
deficiencies; single, large-scale mtDNA deletions, predom- 
inantly found in sporadic cases, are associated with Pear- 
son syndrome (MIM: 557000), Kearns-Sayre syndrome 
(MIM: 530000), or progressive external ophthalmoplegia 
(PEO; OMIM phenotypic series PS157640), as well as late- 
onset PEO due to Mendelian-driven multiple mtDNA dele- 
tions, which have been observed in >20 genetically 
distinct disorders8 (also see GeneReviews in Web Re- 
sources). In addition, cofactor deficiencies and further 
defects of mitochondrial homeostasis—including mito- 
chondrial biogenesis, lipid metabolism, protein import, 
fission and fusion, and quality control—can result in a 
deficiency of more than one OXPHOS enzyme.2 
One protein involved in mitochondrial homeostasis is 
complement component 1 Q subcomponent-binding pro- 
tein (C1QBP; also known as p32). It is an evolutionary 
conserved and ubiquitously expressed multifunctional 
protein and has been reported to be a predominantly mito- 
chondrial matrix protein involved in inflammation and 
infection processes, mitochondrial ribosome biogenesis, 
regulation of apoptosis and nuclear transcription, and 
pre-mRNA splicing.9–15 By analyzing a C1QBP-knockout 
(KO) mouse model, we have previously demonstrated 
that a main function of C1QBP is a combined respira- 
tory-chain complex deficiency due to severely impaired 
mitochondrial protein synthesis.16 Furthermore, the 
Saccharomyces cerevisiae ortholog of human C1QBP, 
MAM33 (mitochondrial acidic matrix protein 33), has 
been shown to localize to the mitochondrial matrix.17 
MAM33-deficient yeast cells show a disturbed mainte- 
nance of the mitochondrial genome, impairment of mito- 
chondrial ATP synthesis, and growth deficiency.17,18 The 
latter can be restored by the introduction of human 
C1QBP cDNA, which demonstrates the evolutionarily 
conserved function of C1QBP homologs among eukary- 
otes.18 In line with the complementation in yeast and find- 
ings in mice, human C1QBP-knockdown (KD) cells also 
exhibit reduced synthesis of mtDNA-encoded OXPHOS 
polypeptides.19 
Here, we report four individuals from unrelated families 
affected by biallelic mutations in C1QBP (MIM: 601269). 
They present with multiple OXPHOS deficiencies and a clin- 
ical spectrum ranging from infantile lactic acidosis, child- 
hood- or adulthood-onset (cardio)myopathy, and PEO. 
 
 
Subjects and Methods 
 
All studies were completed according to local ethical approval 
of   the   institutional   review   boards   of   Technische   Universita¨t 
Mu¨nchen, the University of Milan, the National Research Ethics 
Service Committee North East – Newcastle & North Tyneside 1, 
and Saitama Medical University. In agreement with the Declara- 
tion of Helsinki, all individuals or their guardians gave written 
informed consent before undergoing evaluation and testing, 
which was approved by the ethical committees of the centers 
participating in this study, where biological samples were 
obtained. 
 
 
Subjects 
Individual 1 (S1; family 1 individual II-2) was a boy who died at 
day 18 after experiencing asymmetric ventricular cardiomyopa- 
thy, congenital nephrosis, hypothyroidism, and encephalopathy 
with multiple hemorrhagic events (Table 1). He was born by spon- 
taneous vaginal delivery to healthy, unrelated British parents after 
in vitro fertilization at 34 weeks þ 2 days of gestation. His twin 
brother is unaffected. Oligohydramnios was referenced in the 
antenatal history, and a swollen face, hands, and feet were noticed 
at birth. On the third day, he presented with prolonged cardiore- 
spiratory arrest. He was resuscitated for 2 hr by both mechanical 
(chest compression) and pharmacological (adrenaline, sodium bi- 
carbonate, atropine, and calcium chloride) treatments and was in- 
tubated and ventilated. After resuscitation, he was admitted to 
pediatric intensive care unit with severe metabolic acidosis 
(plasma lactate: 21 mmol/L, normal: 0.5–2.5 mmol/L; base excess 
[BE]: -18.4 mmol/L, normal: -2 to þ2 mmol/L), initial signs of 
kidney failure (anuria; albumin: 15 g/L, normal: 35–40 g/L; urea: 
6.1 mmol/L, normal: 0.8–5.5 mmol/L), and a poor general condi- 
tion (unconscious, not responsive to stimuli, and fixed and dilated 
pupils). An increased level of troponin suggested severe myocar- 
dial damage secondary to his arrest event, and echocardiography 
revealed a dilated and poorly functioning left ventricle. He 
required additional cardiovascular and metabolic support and a 
blood transfusion. Neurological investigations demonstrated 
extensive brain damage: electrical discharges defined as suppres- 
sion bursts and subclinical seizures were recorded by electroen- 
cephalography, and brain MRI showed global cerebral edema 
with a loss of differentiation between gray and white matter, a 
loss of definition of the basal ganglia on T2-weighted images, mul- 
tiple areas of hemorrhage in the bilateral subdural region over 
both cerebral convexities and in the posterior fossa, and subarach- 
noid hemorrhage in the Sylvian fissures and lateral ventricles. 
Although he presented with signs and symptoms of congenital 
nephrosis, his kidney ultrasound showed only general hyperecho- 
genicity. During the clinical course, his neurological conditions 
slightly improved: he was able to open his eyes and respond to 
stimuli, and he showed some movement of the legs and arms in 
the following days. However, lactic acidosis persisted, anuria was 
resistant to pharmacological treatment, and he also developed hy- 
perkalemia and hyperphosphatemia after blood transfusion, 
which required peritoneal dialysis (day 4). The clinical course 
was also complicated by thrombocytopenia on day 6 (which 
required platelet transfusion), evidence of disseminated intravas- 
cular coagulopathy on day 7 (which was treated with fresh frozen 
plasma and cryoprecipitate), and peritonitis on day 9 (which was 
treated with antibiotics). The cause of death on day 18 was respi- 
ratory insufficiency. Kidney histology on autopsy tissue showed 
multifocal and diffuse cortical necrosis, multifocal pyramid necro- 
sis, confluent recent hemorrhages surrounding the pyramids, scat- 
tered cortical tubular microcysts, and partially or completely 
sclerosed glomeruli. The number of glomeruli was slightly higher 
  
 
Table 1. Genetic and Clinical Findings in Individuals with C1QBP Mutations 
Proband 
 
S1 S2 S3 S4 
C1QBP variant 
(GenBank: 
NM_001212.3) 
c.[557G>C];[612C>G] c.[739G>T];[c.824T>C] c.[823C>T];[823C>T] c.[562_564delTAT];[562_ 
564delTAT] 
 
C1QBP variant 
(GenBank: 
NP_001203.1) 
p.[Cys186Ser];[Phe204Leu] p.[Gly247Trp];[Leu275Pro]   p.[Leu275Phe];[Leu275Phe] p.[Tyr188del];[Tyr188del] 
 
 
Origin European descent Asian descent European descent European descent 
Age of onset 4 days birth 5 years 57 years 
Gender male female male male 
 
Current age or age 
of death 
18 days (deceased) 4 days (deceased) 22 years (alive) 70 years (deceased) 
Antenatal findings oligohydramnios, oedematus 
feet, face and hands 
IUGR, oligohydramnios – – 
 
Plasma metabolic 
test results 
 
lactate: 21 mmol/L (normal: 
0.5–2.5) 
lactate: 20 mmol/L 
(normal: 0.5–2.5) 
 
lactate: 3.2 mmol/L (normal: 
0.5–2.5); CPK: 566 U/L 
(normal:  38–174); Met: 
56.2 mmol/L (normal: 14.4–36); 
Tyr: 145 mmol/L (normal: 41.8–
108) 
normal 
 
 
Clinical Signs and Symptoms 
 
Heart cardiorespiratory arrest, 
asymmetric left ventricular 
cardiomegaly 
 
cardiomegaly left ventricular hypertrophy left ventricular hypertrophy 
 
 
Liver – hepatomegaly increased transaminases – 
 
CNS multiple cortical, ventricular, 
and subdural hemorrhages 
and cerebral edema, burst 
suppression-like electrical 
discharges, suclinical seizures 
– NA NA 
 
 
PNS NA NA sensory peripheral neuropathy diffuse neurogenic 
abnormalities and focal 
myogenic in the gluteus 
maximus 
Kidney congenital nephrosis – – NA 
 
Muscle NA NA exercise intolerance with fatigue 
and vomiting 
exercise intolerance, weakness 
 
Eye NA NA astigmatism, amblyopia, 
ptosis, PEO 
 
ptosis, progressive external 
opthalmoplegia 
 
Other hypothyroidism, disseminated 
intravascular coagulopathy 
 
NA NA post-traumatic depression, 
diabetes, sensorineural 
hearing loss 
 
 
Abbreviations are as follows: NA, not available; CPK, creatine phosphokinase; Met, methionine; Tyr, tyrosine; IUGR, intrauterine growth restriction; CNS, central 
nervous system; and PNS, peripheral nervous system. 
 
 
than in normal kidney tissue and showed a different degree of me- 
sangial proliferation. There were also some fibrin thrombi in the 
glomerular capillaries. Necrosis and multifocal areas of hemor- 
rhage were also present in the lungs, adrenals, spleen, and testes. 
Histological examinations of heart autopsy tissue revealed the 
presence of a small recent infarct of the anterior papillary muscle 
and some hemorrhages and sparse neutrophils around a small 
recent fibrous scar of the papillar muscle. The thymus showed 
marked atrophy. The cortex, medulla, and crowded Hassal’s cor- 
puscles were not distinguishable. A pronounced lymphocyte 
depletion was present. 
 
Individual 2 (S2; family 2 individual II-1) was a girl who died at 
4 days of age after suffering from cardiomegaly and lactic acidosis. 
She was the first child of healthy, non-consanguineous Japanese 
parents. Pregnancy was complicated by intrauterine growth re- 
striction and oligohydramnios. She was born pre-term (33 weeks 
of gestation) by emergency cesarean section as a result of fetal 
heart-rate failure. In the immediate postnatal period, she devel- 
oped   metabolic   acidosis   (BE:   -25   mmol/L,   normal:   -2   to 
þ2 mmol/L) and an increased level of lactic acid (9.0 mmol/L at 
day  0,  19.8  mmol/L  at  day  1,  >20  mmol/L  at  day  3,  and 
19.6  mmol/L  at  day  4;  normal:  0.5–2.5  mmol/L).  She became 
  
unconscious and required ventilator support. Cardiomegaly with 
no ventricular or septic hypertrophy was diagnosed by heart ultra- 
sound and a thoracic X-ray scan. A general examination revealed 
that she also presented with mild hepatomegaly, and histological 
examination of a liver biopsy showed marked lipid accumulation. 
Additional neurological signs and symptoms were not reported, 
and brain ultrasound did not reveal any abnormalities. She died 
on the fourth day of life because of cardiorespiratory insufficiency. 
Individual 3 (S3; family 3 individual II-2) is a 22-year old man 
with myopathy, asymmetric ventricular cardiomyopathy, PEO, 
and ptosis. He was born after an uneventful pregnancy to non- 
consanguineous Austrian parents. His sister, who is 3 years older, 
is healthy. Pregnancy and peri- and postnatal adaptations were un- 
remarkable. Birth weight, length, and head circumference were 
within normal limits. His early milestone acquisitions were appro- 
priate for his age. He presented with bilateral hyperopic astigma- 
tism and amblyopia, a first sign of eye muscular weakness, at 
5 years of age and exercise intolerance with fatigue, episodes of 
vomiting, and elevated levels of creatine phosphokinase (CPK) 
1 year later. Left ventricular cardiomyopathy was also diagnosed 
at 8 years of age after heart ultrasound screening. The clinical 
phenotype and increased level of plasma lactate (3.2 mmol/L, 
normal: 0.5–2.2 mmol/L) were suggestive of a mitochondrial dis- 
order. Treatment with L-carnitine, riboflavin, and coenzyme Q 
was initiated but showed only initial and partial improvement. 
The clinical course appeared slowly progressive with the develop- 
ment of mild ptosis at 14 years of age and PEO at 19 years of age. 
Transaminase levels were repeatedly elevated (aspartate transami- 
nase: 73 U/L, normal: 10–50 U/L; alanine transaminase: 61 U/L, 
normal: 10–50 U/L), and liver ultrasound showed no structural 
changes. At the last evaluation, a nerve conduction study revealed 
subclinical signs of sensory peripheral neuropathy, and scotopic 
and photopic bilateral electroretinography showed low ampli- 
tudes. Assessment of exercise intolerance by bicycle ergometry 
confirmed premature fatigue and an increased level of plasma 
lactate (basic lactate: 6.1 and 19.1 mmol/L after exercise, normal: 
0.5–2.2 mmol/L) and CPK (basic CPK: 386 and 566 U/L after exer- 
cise, normal: 38–174 U/L). The cardiac status was stable without 
progression. He was investigated for hearing and kidney function- 
ality, which were shown to be normal. Although he has general- 
ized weakness, he is not compromised in his daily functionality. 
Individual 4 (S4; family 4 individual II-2) was a 61-year-old man 
with late-onset PEO and myopathy. He was born at term as the sec- 
ond of ten brothers and sisters to healthy, non-consanguineous 
Italian parents after an uneventful delivery. No family history of 
neuromuscular disorders or other disorders, except for the prema- 
ture postnatal death of one sister, has been reported. Early devel- 
opment and milestone acquisition were referenced as normal. At 
the age of 57 years, he was admitted to a psychiatric hospital 
because of post-traumatic depression that required intensive phar- 
macological and psychotherapy intervention. He was also diag- 
nosed with diabetes and started treatment with gliclazide. The 
onset of neuromuscular weakness was detected at 59 years of 
age, and rapidly progressive exercise intolerance limited his func- 
tionality: he was not able to stand for long periods of time or raise 
his arms. He was admitted to the hospital at 61 years of age 
because of the development of ptosis, severe constipation, and 
weight loss (10 kg in 5 months). At the neurological examination, 
he presented with important bilateral eyelid ptosis (left > right), 
PEO in all directions, mild to moderate proximal weakness, mild 
and diffuse hypotrophy, and an unstable gait due to  lower- 
limb weakness. Electromyography showed diffuse signs of chronic 
neurogenic rearrangement and focal myogenic signs in the gluteus 
maximus. A metabolic workup including plasma lactate, creatine 
kinase, transaminases, and thyroid function was normal. He was 
extensively investigated, and additional clinical findings were 
identified: left ventricular hypertrophy, left ventricular overload, 
and signs of previous myocardial infarction by electrocardiog- 
raphy; bilateral and symmetric sensorineural hypoacusia by audi- 
ometry; and multiple gastric erithematous areas by esophagogas- 
troduodenoscopy. Proband S4 and his family refused additional 
investigations. He died in his 70s for an unknown reason. 
 
Exome Sequencing 
We applied next-generation exome sequencing with whole- 
exome sequencing (WES) or a mitochondrial exome library 
(‘‘MitoExome’’) to the individuals’ DNA extracted from peripheral 
blood. Probands S1–S3 were investigated by WES.4,5,20 In brief, 
coding regions were enriched with a SureSelect Human All Exon 
V5 Kit (Agilent) or TruSeq (Illumina) and then sequenced as 
100-bp paired-end runs on an Illumina HiSeq 2000, 2500, or 
4000. Reads were aligned to the human reference genome 
(UCSC Genome Browser build hg19) with the Burrows-Wheeler 
Aligner (v.0.7.5 a).21 Single-nucleotide variants and small inser- 
tions and deletions (indels) were detected by SAMtools 
(v.0.1.19). Proband S4 was investigated by MitoExome as previ- 
ously described,22 and only rare recessive variants in highly 
conserved amino acid residues were considered pathogenic by 
PolyPhen-2 or SIFT (Table S1). 
We used Sanger sequencing to confirm the identified mutations 
and test the carrier status of unaffected family members. 
 
mDNA Analysis 
mtDNA was amplified with two primer pairs, giving a 16,147 bp 
(F1) or 15,679 bp (F2) fragment. 5 mL of the amplified mtDNA 
was loaded onto a 0.7% agarose gel and separated at 80 V for 
1  hr.  The  marker  l/HindIII  (the  bacteriophage  l  digested  by 
HindIII) was used.23 Southern blot was performed as previously 
described.24 mtDNA copy number was determined by quantitative 
real-time PCR with four different nuclear and two mitochondrial 
PCR amplicons.25 The relative amount of mtDNA versus nuclear 
DNA was calculated by the 2-DDCT method.25 
 
OXPHOS Enzyme Activities 
Muscle tissues (20–100 mg) were homogenized in extraction 
buffer (20 mM Tris-HCl [pH 7.6], 250 mM sucrose, 40 mM KCl, 
and 2 mM EGTA). The post-nuclear supernatant isolated by centri- 
fugation at 600 3 g and containing the mitochondrial fraction was 
used for measurement of enzyme activities. OXPHOS enzyme and 
citrate synthase (CS) activity was measured spectrophotometri- 
cally as previously described.26–29 
 
Western Blot Analysis 
Skeletal muscle and fibroblast homogenates were obtained accord- 
ing to previously described methodologies.30 30–40 mg (S1–S3) 
and 20 mg (S4) of whole-cell protein extracts were separated by 
SDS polyacrylamide (12%) electrophoresis and then wet transferred 
to polyvinyl difluoride (PVDF) membranes. For S4, a 4%–12% 
gradient gel was used. Immunological detection of proteins was car- 
ried out with the following primary antibodies: C1QBP (ab24733, 
Abcam), b-actin (A1978, Sigma), a-tubulin (ab7291, Abcam), and 
OXPHOS complex-specific antibodies (NDUFS3 [ab14711, Abcam], 
NDUFB8 [ab110242, Abcam], NDUFA9 [MS111, Molecular Probes], 
  
SDHA [459200, MitoSciences], SDHB [ab14714, Abcam], UQCRC2 
[ab14745, Abcam], COXI [ab14705, Abcam], COXII [ab110258, 
Abcam], COXIV [ab14744, Abcam], and ATP5A [ab14748, Abcam]). 
Species-appropriate horseradish-peroxidase-conjugated secondary 
antibodies (DAKO, P0399, and P0260) were used. 
 
BN-PAGE Analysis 
For blue-native polyacrylamide-gel electrophoresis (BN-PAGE), n-
dodecyl b-D-maltoside-solubilized mitochondrial membranes were 
prepared from isolated fibroblasts and muscle mitochondria 
according to previously described methodologies.30,31 In brief, 
100 mg of mitochondrial extracts was loaded onto a 4%–16% 
native polyacrylamide BisTris gradient gel (Life Technologies) 
and separated electrophoretically. For western blot analysis, 
samples separated by BN-PAGE were transferred onto PVDF 
membranes and subjected to the following primary antibodies: 
NDUFB8 (complex I [CI]), SDHA (complex II [CII]), UQCRC2 
(complex III [CIII]), COXI (complex IV [CIV]), and ATP5A (com- 
plex V [CV]). 
 
Immunofluorescence Staining 
Immunofluorescence was performed according to a modified 
version of the previously published protocol.32 Fibroblasts were 
grown on coverslips, washed with PBS, and fixed with 4% formal- 
dehyde for 15 min at room temperature. After additional washes 
with PBS, coverslips were permeabilized with 1% Triton X-100 
for 5 min, washed, and blocked in 5% fetal bovine serum (FBS) 
for 1 hr at room temperature. A solution of primary antibodies 
(1:500 polyclonal rabbit anti-TOM20, sc-11415, Santa Cruz;  
1:250 monoclonal mouse anti-C1QBP, ab24733, Abcam) in 5% 
FBS was prepared and used for incubating the coverslips for 1 hr 
at room temperature. After PBS washings, coverslips were incu- 
bated with secondary antibodies (1:1,000 Alexa-Fluor-488-conju- 
gated goat anti-mouse IgG, A11001, Invitrogen; 1:1,000 Alexa- 
Fluor-594-conjugated goat anti-rabbit IgG, A11012, Invitrogen) 
in 5% FBS for 1 hr at room temperature while being protected 
from light. After the final washes, coverslips were mounted 
(ProLong Gold antifade reagent with DAPI, P36941, Invitrogen) 
on glass slides. Microscopy was carried out with a Zeiss LSM 880 
confocal microscope, and acquired images were processed with 
ImageJ.33 
 
High-Resolution Respirometry 
Mouse embryonic fibroblasts (MEFs) were seeded at a density of 
20,000 cells/well in 80 mL of culture media in an XFe 24-well 
cell-culture microplate (Seahorse Bioscience) and incubated over- 
night at 37oC in 5% CO2. Culture medium was replaced with  
180 mL of bicarbonate-free DMEM, and cells were incubated at 
37oC for 30 min before measurement. The oxygen-consumption 
rate (OCR) was measured with an XFe 24 Extracellular Flux 
Analyzer (Seahorse Biosciences) and determined (1) with no 
additions (basal respiration), (2) after the addition of 0.5 mM oli- 
gomycin (indicating ATP  production), (3)  after the  addition  of 
1 mM  carbonyl  cyanide 4-(trifluoromethoxy) phenylhydrazone 
(maximal respiration), and (4) after the addition of 1 mM rote- 
none and antimycin A (non-mitochondrial respiration) (addi- 
tives were purchased from Sigma at the highest quality). The 
difference in OCR after the addition of oligomycin and the non-
mitochondrial  respiration  specify  proton  leakage,  and the 
difference between basal and maximal respiration determines 
spare capacity. 
Construction and Validation of C1QBP Expression 
Vector 
The mouse C1QBP variants p.Glu244Trp and p.Leu272Pro (corre- 
sponding to the human variants p.Gly247Trp [c.739G>T] and 
p.Leu275Pro [c.824T>C], respectively, found in probands S2 and 
S3) were generated from pcDNA3-p32-IRES-GFP by PCR-based 
site-directed mutagenesis and confirmed by sequencing. To 
examine protein expression,  we  transfected  C1qbp-KO  MEFs  
with the C1qbp expression vector by using the transfection reagent 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. GFP expression served as an internal control. 
 
mRNA Quantification 
Total RNA from wild-type (WT) MEFs and C1qbp-KO MEFs trans- 
fected with various C1qbp expression  vectors  was  isolated  with 
an RNeasy Mini Kit (QIAGEN) according to the manufacturer’s in- 
structions. The concentration and purity of total RNA were 
measured on a NanoDrop spectrophotometer (NanoDrop Tech- 
nologies). Reverse transcription of 1 mg of total RNA was performed 
with a PrimeScript RT Reagent Kit (TAKARA). Mouse C1qbp mRNA 
and mouse 18S ribosomal RNA (control) were detected by quanti- 
tative PCR with SYBR Premix Ex Taq II (TAKARA) and a thermal 
cycler (StepOnePlus, Applied Biosystems). Primers were as follows: 
50-CGCGGTTCTATTTTGTTGGT-30 (18S rRNA forward), 50-AGTCG 
GCATCGTTTATGGTC-30 (18S rRNA reverse), 50-GGCCTTCGTTG 
AATTCTTGA-30  (C1qbp  mRNA  forward),  and  50-  GCCTCATCT 
TCGTGTCCAAT-30 (C1qbp mRNA reverse). An unpaired Student’s 
t test was used to determine statistical differences between two 
groups. Values of *p < 0.05, **p < 0.01, and ***p < 0.005 were 
considered to be statistically significant. 
 
 
Results 
 
Exome Sequencing and Variant Prioritization 
Clinical research centers from Austria, Germany, Japan, the 
UK, and the US independently achieved and subsequently 
shared results from WES or MitoExome sequencing anal- 
ysis on individuals with suspected mitochondrial disease. 
WES of probands S1–S3 failed to identify likely or known 
disease-associated genetic variants but did reveal rare bial- 
lelic variants (minor allele frequency [MAF] < 0.1% in 
public and in-house databases) in C1QBP (GenBank: 
NM_001212.3). Screening of our in-house database of 
more than 10,000 WES datasets of individuals with non- 
mitochondrial disease revealed no additional individual 
with biallelic rare variants in C1QBP. Filtering for genes 
coding for mitochondrial proteins in probands S1–S3 re- 
vealed that C1QBP was the only gene with biallelic 
variants.34 Likewise, MitoExome sequencing prioritized 
biallelic variants in C1QBP in proband S4. Altogether, we 
identified four individuals harboring recessive variants in 
C1QBP (Table 1 and Figure 1A). Although none of the iden- 
tified variants are predicted to cause a loss of function, all 
are predicted to be pathogenic (Figure 1B and Table S1). 
Human C1QBP (UniProt: Q07021) forms a homotrimer 
arranged into a doughnut-shaped structure with an unusu- 
ally asymmetric charge distribution on the surface. The 
variants p.Cys186Ser, p.Gly247Trp, and p.Leu275Pro are 
  
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. C1QBP Variants and Gene and Protein Structure 
(A) Pedigrees of the investigated families (S1–S4) affected by recessively inherited C1QBP variants. Affected individuals are indicated by 
closed symbols. Both variants in proband S2 have been confirmed to be compound heterozygous by phasing of WES data. 
(B) Gene structure with exons and introns shows the localization of the investigated gene variations. Conservation of the affected amino 
acid residues is presented in the alignment of homologs across different species. Exons are highlighted in blue. The size of the introns was 
reduced 10-fold. MTS is the mitochondrial target sequence. MAM33 (mitochondrial acidic matrix protein 33) is the Saccharomyces 
cerevisiae homolog of C1QBP. 
(C) Inspection of the protein structure was performed with PyMOL (PDB: 1P32). A monomer is presented on the left, and the trimer is in 
the center. The electrostatic field of the trimer is indicated to the right (negative polarity, red; positive polarity, blue). Affected residues are 
colored in one of the monomers: Cys186, green; Tyr188, blue; Phe204, red; Gly247, magenta; and Leu275, orange. 
 
all localized in important structural domains of the pro- 
tein. Specifically, amino acid residue Cys186 is localized 
on the b5 strand of the protein,  Gly247  is  located  on 
the hydrogen-bonded turn of  the  protein,  and  Pro275 
is located on the aC helix (Figure 1C). In contrast, 
p.Phe204Leu and p.Tyr188del are localized on the coiled- 
coil region between the b5 and b6 strands.9 All C1QBP var- 
iants have been confirmed by Sanger sequencing. Homo- 
zygosity or compound heterozygosity was confirmed by 
segregation analysis in families 1 and 3  and  by  cloning 
and sequencing of genomic DNA in proband S2, whereas 
no DNA was available from the parents of proband S4 for 
T  
A B Figure 2. Western Blot Analysis of C1QBP 
Cell lysates isolated from (A) the skeletal 
muscle of affected probands S1, S3, and 
S4 and (B) fibroblasts  from  probands  S1–
S3 and age-matched control individuals (C1 
and C2) were analyzed. Fibroblasts from 
proband S4 and skeletal muscle from 
proband S2 were  not  available.  b-actin 
and a-tubulin were used as loading con- 
trols. All experiments were repeated at least 
two times, and representative images are 
shown. Number of repeats: (A) n ¼ 3 (S1) 
and n ¼ 2 (S3 and S4); (B) n ¼ 2 (S1–S3). 
 
 
 
 
 
 
validation of the deletion’s homozygosity. The C1QBP 
variants found in proband S2 have previously been 
suggested as likely candidates but have not been validated 
so far.4 
 
Mitochondrial Respiratory-Chain Activities 
The identification of rare, biallelic C1QBP variants in four 
individuals with clinically and biochemically confirmed 
mitochondrial disease adds further evidence for their 
functional relevance. Typical of mitochondrial disorders, 
the C1QBP defect resulted in a spectrum of manifestations 
that ranged from infantile lactic acidosis (probands S1 and 
S2) to childhood myopathy (proband S3) to late-onset 
myopathy with PEO (proband S4). However, in all indi- 
viduals, cardiac symptoms were present, and respiratory- 
chain activities in  muscle  or  liver  homogenates  showed  
a severe combined deficiency of respiratory-chain activ- 
ities (complexes I,  III,  and  IV).  This  was  accompanied  
by  an  increased  level  of  mitochondrial  mass   index   
(CS) in the muscle of probands S3  (511  mUnits/mg  
protein; normal:  150–325  mUnits/mg  protein)  and  S4  
(151 mUnits/mg protein; normal: 137 5 15 mUnits/mg 
protein; see Table S2). 
Enzymatic activities of liver homogenates from proband 
S2 revealed a more general downregulation of the 
OXPHOS  complexes. In addition to the complex  I  (to 
5%), III (to 14%), and IV (to 11%) deficiency, a reduc- tion 
in complex II (to 37%) activity was also found (Table S2). 
In addition, decreased COX histochemical activity was 
found in proband S1 (affecting up to 75% of all muscle 
fibers); occasional COX-deficient fibers were observed in 
muscle from probands S3 and S4, notably at levels above 
those expected to be detected in age-matched control indi- 
viduals as a result of somatic mtDNA mutation. Ragged-red 
fibers were present in the muscle of probands S1 and S3 
(Table S2). Histopathological analysis of the muscle of pro- 
band S4 showed moderate variability 
in fiber size, a moderate increase in fi- 
ber splitting and central nuclei, and a 
slight increase in connective tissue. 
The identification of four different 
alleles in four affected individuals 
with a similar clinical and biochemical 
phenotype from four families estab- 
lishes C1QBP variants as confidently implicated in reces- 
sively inherited mitochondrial disease. 
 
C1QBP and OXPHOS Protein Levels 
Given that previous studies have reported C1QBP as a 
mitochondrial-matrix protein, we wanted to  validate  
the localization of C1QBP in mitochondria. Immuno- 
cytochemical staining using C1QBP-specific antibodies 
confirmed the mitochondrial localization of the protein 
(Figure S1).9,13,17 Given that all identified C1QBP variants 
affect only one amino acid, the consequences on protein 
stability were unclear. We therefore investigated available 
skeletal-muscle biopsy material and primary fibroblast 
cultures established from individuals to analyze the 
significance of C1QBP variants in disease. Western blot 
analysis showed that C1QBP levels were not detectable in 
muscle (Figure 2A) and considerably decreased in fibro- 
blasts (Figure 2B), supporting the notion that correspond- 
ing C1QBP variants adversely affect the stability of the 
protein. 
Consistent with the findings of enzymatic investigations 
from muscle, a decrease in complex I and complex IV sub- 
units was present in muscle homogenates derived from 
probands S1, S3, and S4 (Figure 3A). In addition, UQCRC2 
was decreased in the muscle of probands S3 and S4 
(Figure 3A). In contrast, OXPHOS protein levels were 
normal or only marginally lowered in fibroblasts from pro- 
bands S1 and S3, whereas proband S2 showed a marked 
loss of complex IV subunits (Figure 3B). Surprisingly, the 
steady-state levels of complex III subunits were higher 
in the fibroblasts of proband S3 than in control cells 
(Figure 3B). 
Decreased protein levels of subunits of respiratory-chain 
complexes usually reflect assembly defects, but they can 
also be suggestive of other mitochondrial disorders, 
including mitochondrial translation defects. We therefore 
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Figure 3. Steady-State Levels of OXPHOS Complex Subunits 
(A) Western blot analysis of OXPHOS subunits in skeletal-muscle lysates from control individuals (C1 and C2) and probands S1,  
S3, and S4. 
(B) Western blot analysis of OXPHOS subunits in skin fibroblasts from probands S1–S3 and age-matched control individuals (C1–C3). 
OXPHOS-subunit-specific antibodies were used against NDUFB8 or NDUFA9 (CI); SDHA or SDHB (CII); UQCRC2 (CIII); COXI, COXII, or 
COXIV (CIV); and ATP5A (CV). Cytosolic b-actin and mitochondrial markers porin (VDAC) and SDHA were used as loading controls. All 
experiments were repeated at least twice, and representative western blots are shown. Number of repeats: (A) n ¼ 3 (S1) and n ¼ 2 (S3 and 
S4); (B) n ¼ 4 (S1) and n ¼ 2 (S2 and S3). 
 
 
analyzed the steady-state levels of intact respiratory-chain 
complexes by BN-PAGE. A decrease in intact steady-state 
levels of complexes I, IV, and V was present in the muscle  
of probands S1 and S3 (Figure 4A). Only a slight decrease in 
complex IV was obvious in proband S1. The level of com- 
plex II was normal. In agreement with the decrease in the 
steady-state levels of complex I and complex IV subunits in 
the fibroblasts of individual S2, decreased levels of assem- 
bled complex I and complex IV were found (Figure  4B). 
The level of complex III was  normal  in  proband  S2 
(Figure 4B). No alterations in the steady-state levels of 
intact complexes were detectable in fibroblasts from pro- 
bands S1 and S3 (Figure 4B). 
 
Complementation Studies with Mouse Fibroblasts 
We recently showed that a KO of the orthologous C1qbp in 
MEFs caused impaired mitochondrial respiration associ- 
ated with reduced levels of respiratory-chain complexes I, 
III, and IV.16 C1qbp-/- MEFs recapitulate the human dis- 
ease phenotype by displaying multiple OXPHOS defects. 
We  therefore took advantage of the strong phenotype in  
the mouse system to investigate the functional properties  
of the C1QBP variants identified  in probands S2 and S3.  
We modeled the variants in the mouse cDNA and ex- 
pressed them in C1qbp-/- MEFs. With mitochondrial com- 
plex IV subunits I (COXI) and III (COXIII) as markers, only 
re-expression of mouse WT C1qbp rescued the amount of 
  
A Figure 4. BN-PAGE of OXPHOS Com- 
plexes 
One-dimensional BN-PAGE analysis of 
OXPHOS complexes was performed on 
mitochondrial lysates isolated from pro- 
bands’ (A) skeletal muscle (S1 and S3) 
and (B) fibroblasts (S1–S3) and age- 
matched control individuals (C1 and C2). 
The assembly of OXPHOS complexes was 
assessed by western blotting with anti- 
bodies against NDUFB8 (CI), SDHA (CII), 
UQCRC2 (CIII), COXI (CIV), and ATP5A 
(CV). An antibody against complex II sub- 
unit SDHA was used as a loading control. 
The ATP5A antibody detected two bands: 
the fully assembled complex V (F0F1) and 
the soluble F1 subunit. The asterisk indi- 
B cates  a  longer  exposure  time  for  the  CV 
F1 subunit. All experiments were repeated 
at least twice, and representative images 
are shown. Number of repeats: (A) n ¼ 4 
(S1) and n  ¼ 2  (S3);  (B)  n  ¼ 4  (S1)  and  
n ¼ 2 (S2 and S3). 
 
state level, OXPHOS protein expres- 
sion, and enzyme activities. 
 
 
 
 
 
 
 
complex IV protein (Figure 5A, upper panel, lane 3), con- 
firming causality between loss of C1QBP and diminished 
levels of OXPHOS subunits. Expression of C1qbp cDNA 
coding the p.Gly247Trp variant (p.Gly244Trp in mice) re- 
sulted in levels comparable to those of the native form 
but only partially rescued COX subunit levels (Figure 5A, 
upper panel, lane 4), confirming a functional defect. 
Expression of C1qbp cDNA encoding the p.Leu275Pro 
variant (p.Leu272Pro in mice) did not result in a detectable 
C1QBP and was consequently not able to rescue mito- 
chondrial COXI or COXIII levels (Figure 5A, upper panel, 
lane 5). GFP expression under the internal ribosome entry 
site and the C1qbp mRNA level were comparable to those 
of the WT (Figures 5A and 5B), suggesting that the low 
expression of p.Leu272Pro is due to reduced protein 
expression or increased protein turnover. 
To validate the consequences on respiration, we per- 
formed high-resolution respirometry with C1qbp-deficient 
MEFs expressing cDNAs encoding the WT, p.Gly244Trp, 
p.Leu272Pro, or an empty vector. Reduced basal and 
maximal respiration, proton leakage, and ATP production 
were found in cells non-transduced or transduced with 
the empty vector (Figures 5C and 5D). Consistent with the 
results of the western blot analysis, p.Gly244Trp resulted 
in a partial recovery, whereas p.Leu272Pro was in a range 
similar to that of the empty vector (Figures 5C and 5D). 
In summary, complementation with WT, but not 
mutant, C1qbp in C1qbp-/- MEFs restored C1QBP steady- 
mtDNA analysis 
Given that proband S3  presented 
with PEO, which is often associated 
with mtDNA rearrangements, ana- 
lyses of mtDNA copy number and 
multiple mtDNA deletions were performed in all available 
muscle and fibroblast cell lines (Table S2). These revealed 
that mtDNA copy number was 250% higher in the 
muscle of proband S1 and ~600% higher in the liver of 
proband S2 than in control cells, but there was no evi- 
dence of mtDNA rearrangements (Table S2). Although 
the level of mtDNA was within the normal range in muscle 
samples from probands S3 and S4, long-range PCR and 
Southern blotting both revealed evidence of multiple 
mtDNA deletions (Figure 6). Concordant with other 
investigations of fibroblasts from proband S3, no signifi- 
cant finding (borderline) was obtained in this individual’s 
cell line. 
 
 
Discussion 
 
Here, we report four individuals from unrelated families 
where biallelic mutations in C1QBP cause a combined res- 
piratory-chain enzyme deficiency. All variants are rare with 
a MAF < 0.00005 in the ExAC Browser, and no other indi- 
vidual in our in-house database of >10,000 WES datasets 
carries rare biallelic variants in this gene. The finding of 
four individuals with a defect in mitochondrial energy 
metabolism (among 2,000 individuals investigated) pre- 
sents a genome-wide-significant enrichment of biallelic 
C1QBP variants (p < 0.001, Fisher’s exact test) in compari- 
son with samples from non-mitochondrial disorders. In 
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Figure 5.    Complementation Studies Using C1qbp-/- Mouse Fibroblasts 
(A) Quantification of C1QBP, COXI, and COXIII levels. Top: WT or C1qbp KO MEFs were transfected with the pcDNA3-C1qbp-IRES-GFP 
plasmid for 48 hr. Western blotting on total cell extracts was performed with anti-C1QBP, anti-COXI, anti-COXIII, anti-GFP, and anti- 
VDAC antibodies. VDAC was used as the loading control. Bottom: the mean ratios of band densities in transfected MEFs from blots are 
shown. Cells transfected with expression constructs for p.Gly244Trp and p.Leu272Pro variants show significantly lower amounts of 
mature C1QBP and mitochondrial-DNA-encoded proteins (COXI and COXIII). The results represent the mean 5 SD of three indepen- 
dent experiments. ***p < 0.005 versus WT transfectant. 
(B) Relative mRNA expression of C1qbp alleles normalized to mouse 18S rRNA by quantitative real-time PCR. The results represent the 
mean 5 SD of three independent experiments. 
(C and D) Oxygen consumption rate (OCR) profile (C) and histogram of C1qbp KO cells transfected with WT and mutant C1qbp plasmid 
(D). The histogram shows the basal respiration rate (basal), ATP production rate (ATP), and maximal respiration rate (maximal) calcu- 
lated from OCR profiles. Data show the mean 5 SD of triplicated assays. **p < 0.01 and ***p < 0.005 versus WT transfectant. 
 
addition, all variants are predicted to be deleterious by 
several prediction programs. 
To validate the impact of the rare C1QBP variants at the 
functional level, we took advantage of three established re- 
sources: biopsy tissues, primary fibroblast cell lines from 
three affected individuals, and C1qbp-/- MEFs. Mitochon- 
drial localization of C1QBP was shown by immunohisto- 
chemical staining in fibroblasts. Immunodecoration using 
C1QBP-specific antibodies in muscle-biopsy material ob- 
tained from all individuals failed to detect C1QBP, indi- 
cating a loss of function. However, when investigating 
the probands’ fibroblasts, we detected low but substantial 
amounts of C1QBP in all cell lines, most likely reflecting 
different expression and turnover rates between muscle 
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A B Figure 6. Long-Range PCR and Southern 
Blot of Individuals with Multiple mtDNA 
Deletions and Control Individuals 
(A) Long-range PCR of S3. 
(B) Southern blot of proband S4. mtDNA 
was amplified with two primer pairs, giv- 
ing 16,147 bp (F1) and 15,679 (F2) bp frag- 
ments. 5 mL of the amplified mtDNA was 
loaded onto a 0.7% agarose gel and sepa- 
rated at 80 V for 1 hr.  Abbreviations are    
as follows: S3M, muscle of proband S3;  
S3F, fibroblasts of proband S3; S4, muscle 
of   proband   S4;   M,   marker   l/HindIII; 
C1–C3: control cells. 
 
 
and fibroblasts. These data argue against a loss of function 
and for an adverse effect on protein stability of the identi- 
fied C1QBP variants; this could lead to depletion of C1QBP 
in some tissues with higher turnover rates. In any case, the 
data provide additional evidence for the functional rele- 
vance of the C1QBP variants. 
All individuals showed a severe combined deficiency of 
respiratory-chain complexes (I, III, and IV) in muscle or 
liver homogenates. These findings are in line with observa- 
tions in yeast and mice models, where the deficiency of 
the C1QBP orthologs resulted in impairment of mito- 
chondrial ATP synthesis or a combined deficiency of respi- 
ratory-chain complexes, respectively.16–18 For both the 
p.Gly247Trp and p.Leu275Pro variants, this deficiency 
could be rescued by expression of human WT C1QBP. We 
therefore leveraged the respiratory-chain deficiency in 
C1qbp-/- MEFs  and  employed  it  to  screen  for  functional 
complementation by the human mutations. We tested 
two alleles, and whereas one allele only partially rescued 
the phenotype of the fibroblasts, the other did not func- 
tion at all (Figure 5). With these experiments, we provide 
convincing evidence that the identified C1QBP mutations 
cause a combined respiratory-chain deficiency. Analogous 
to findings in mice, biallelic loss-of-function C1QBP vari- 
ants might be embryonically lethal in humans. 
Mutations in half of the known mitochondriopathy- 
associated genes result in a combined deficiency of respira- 
tory-chain enzymes.2 Combined defects are typically due 
to deficiencies in mtDNA replication, transcription, or 
translation. Experiments on KO mouse and KD human 
cells argued for a role of C1QBP in mitochondrial protein 
synthesis.16,19 Investigations on biopsy tissue from indi- 
viduals with C1QBP variants confirmed this observation. 
We found lower levels of various subunits of the respira- 
tory chain in these samples than in age-matched control 
samples (Figures 3 and 4), whereas RNA expression studies 
on one cell line did not reveal any alterations in the level of 
mitochondrial transcripts (data not shown). As expected 
from earlier complementation studies, a role of C1QBP in 
protein synthesis seems to be a conserved function of 
C1QBP in mitochondria. 
Interestingly, the yeast KO cells additionally showed a 
disturbed maintenance of the mitochondrial genome, a 
feature that has not been observed in higher eukaryotes 
so far but is also not very specific in yeast given that it is 
frequently found to be a result of impaired OXPHOS in 
these cells.18 Multiple mtDNA deletions could also explain 
a combined respiratory-chain deficiency with normal com- 
plex II activity. However, multiple deletions were only 
detectable in the muscle of two probands (S3 and S4), 
both of whom had a later onset in either childhood or adult- 
hood. Because we found no evidence of variable mtDNA de- 
letions or mtDNA depletion in the early-onset probands S1 
and S2, we can be confident that their respiratory-chain 
deficiency was not caused by a disturbed maintenance of 
the mitochondrial genome. Nevertheless, in humans there 
is no evidence that multiple mtDNA deletions appear as a 
result of impaired OXPHOS, indicating an additional func- 
tion of C1QBP in the maintenance of the human mito- 
chondrial genome. Given that all cells investigated so far 
are acute KD or embryonic fibroblasts and, in the case of 
S1 and S2, are based on biopsies taken in the first week of 
life, the accumulation of detectable mtDNA deletions in 
C1QBP deficiency is likely to occur over considerable 
time. Wang et al. have reported on an interaction between 
C1QBP and RECQ4, a helicase suggested to participate in 
mtDNA maintenance.35 They describe a RECQ4 mutant 
that failed to interact with C1QBP, which led to increases 
in mtDNA copy number and mitochondrial dysfunction. 
Such scenarios indicate multiple functions of C1QBP in 
mitochondria. Indeed, a number of mitochondrial interac- 
tion partners of C1QBP have been identified by proteomic 
studies.36 They include a number of genes involved in iron- 
sulfur biogenesis (BOLA3 [MIM: 614299], LYRM1 [MIM: 
614709], LYRM2, LYRM4 [MIM: 613311], and LYRM5) or 
OXPHOS subunits (ATP5A1 [MIM: 164360], C17ORF89, 
COX6B1 [MIM: 124089], NDUFA4 [MIM: 603833], 
NDUFAF4 [MIM: 611776], and NDUFS3 [MIM:  603846]), 
as well as factors involved in the maintenance of the 
mitochondrial morphology (C2ORF47 [MIM: 617267], 
CHCHD2 [MIM: 616244],  and CHCHD10 [MIM: 615903]) 
and the mitochondrial genome (TFAM [MIM: 600438]). 
The multiple interaction partners of C1QBP point to a 
multifunctional chaperone role of the protein.37 
C1QBP defects manifested with a spectrum of symptoms 
ranging from infantile lactic acidosis (in probands S1 and 
  
S2) to childhood myopathy, PEO, and later peripheral neu- 
ropathy (in proband S3) to adult-onset myopathy with 
PEO (in proband S4). All individuals presented with major 
cardiac symptoms, which resulted in early death in the 
neonatal form and were rather stable in individuals with 
later presentation. A very recently established cardiomyo- 
cyte-specific deletion of C1qbp resulted in contractile 
dysfunction, cardiac dilatation, and cardiac fibrosis and 
thereby confirmed an important function of C1QBP in 
the heart.38 Decreased COXI and COXIII expression 
confirmed the mitochondrial dysfunction that resulted 
in cardiomyopathy at the age of 2 months and a median 
lifespan of approximately 14 months.38 
In addition, the two individuals with a late disease onset 
presented with PEO and variable mtDNA deletions. The 
clinical manifestation of disorders with deletions in the 
mitochondrial genome is heterogeneous but often in- 
cludes PEO.2 In the group of disorders with multiple 
mtDNA deletions, cardiomyopathy is a rare symptom. It 
is rarely reported in individuals with variants in POLG 
(MIM: 258450)39–41 and TWNK (MIM: 609286)42 and has 
been reported in just a single individual with pathogenic 
variants in MGME1 (MIM: 615084).43 It is more commonly 
associated with autosomal-recessive deficiency of SLC25A4 
(cardiomyopathy types of the disease [MIM: 617184 and 
615418]), another mtDNA maintenance gene, although 
variable mtDNA deletions are usually associated with 
dominant pathogenic variants in this gene. 
Numerous functions in various cellular organelles have 
been reported for C1QBP.16 The clinical manifestation of 
our cohort of probands with C1QBP deficiency was mainly 
attributed to defects in mitochondrial energy metabolism. 
No signs of immunologic dysfunction could be associated 
with the complement system. 
Given our observations, the main functions of C1QBP 
reside within the mitochondrial compartment. How- 
ever, the exact mechanism leading to a reduction of 
OXPHOS enzymes remains unclear, especially in the 
neonatal form. 
In summary, we present four individuals with C1QBP 
mutations characterized by combined respiratory-chain 
deficiency and increased lactate. Disease onset was vari- 
able, including intrauterine onset, oligohydramnios, and 
neonatal cardiomyopathy leading to early death. Later 
onset in childhood or adulthood was associated with exer- 
cise intolerance, PEO, and multiple mtDNA deletions. 
Cardiomyopathy was found in all forms, which is a rela- 
tively unusual presentation in individuals with multiple 
mtDNA deletions. Peripheral neuropathy seems to be an 
issue; however, the central nervous system seems to be 
spared. 
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